(78 days)
The Candela Family of Pulse Dye Laser Systems is indicated for the following uses in:
General Surgery: Photocoagulation of benign cutaneous vascular lesion and benign cutaneous lesions.
Dermatology/Plastic Surgery: For treatment of benign cutaneous vascular lesion, such as facial and leg telangiectasia, rosacea, port wine stains, hemangioma, angioma, spider angioma, Poikiloderma of Civatte, and benign cutaneous lesions, such as warts, scars, striae and psoriasis. and the treatment of wrinkles.
Treatment of Inflammatory Acne Vulgaris
Gynecology: Photocoagulation of benign cutaneous lesion and benign vascular lesion in gynecology.
Podiatry: Treatment of benign cutaneous lesions, such as warts.
New Indication: Treatment of Benign Epidermal Pigmented Lesions
The Candela Family of Pulse Dye Laser Systems are flash-lamp excited pulsed dye medical lasers, controlled by an embedded microprocessor., to be used for the following uses in: General Surgery: Photocoagulation of benign cutaneous vascular lesion and benign cutaneous lesions. For treatment of benign cutaneous vascular lesion, such as facial and leg Dermatology/Plastic Surgery: telangiectasia, rosacea, port wine stains, hemangiomas, angioma, Poikiloderma of Civatte, and benign cutaneous lesions, such as warts, scars, striae and psoriasis. and the treatment of wrinkles. Treatment of Inflammatory Acne Vulgaris
Gynecology: Photocoagulation of benign cutaneous lesion and benign vascular lesion in gynecology. Podiatry: Treatment of benign cutaneous lesions, such as warts.
New Indication: Treatment of Benign Epidermal Pigmented Lesions
The Lasers may be used with the Candela Dynamic Cooling Device, which provides a short burst of cryogen spray prior to firing the laser pulse. The laser output energy is delivered via an optical fiber to a hand piece. The cryogen, which is housed within the laser enclosure, is delivered via a hose to a nozzle located in the hand piece . The Candela Family of Pulsed Dye Laser Systems are equipped with safety interlock systems to protect patients and operators. Users of the device make selections from an onboard control panel to regulate operation during treatment.
The provided text is a 510(k) summary for the Candela Family of Pulsed Dye Laser Systems. It describes the device, its intended uses, and claims substantial equivalence to previously marketed devices. However, it does not contain a study that proves the device meets specific acceptance criteria.
The document states:
- "As a laser product, the Family of Pulsed Dye Laser Systems are required to conform and do conform to the Laser Performance Standard (21 CFR 1040). In addition the lasers conform to the Harmonized Standard EN 60601 1-2, Part 2 established by and required by the European Community." This indicates compliance with general safety and performance standards for laser products, but these are not acceptance criteria tied to a specific clinical performance study for the device's effectiveness for a new indication.
- "The Candela Family of Pulsed Dye Laser Systems is equivalent in key design aspects, functional features and indications for use as the predicate devices for the treatment of epidermal pigmented lesions. On the basis of similarities in functional features, method of operation, and intended uses, Candela Corporation believes that the Candela Family of Pulsed Dye Laser Systems are substantially equivalent to the predicate devices." This is the core of a 510(k) submission: demonstrating substantial equivalence, not necessarily providing new clinical data proving efficacy against specific acceptance criteria.
Therefore, based on the provided text, I cannot complete a table of acceptance criteria and reported device performance directly from a study. There is no clinical study described that evaluates the device's performance against specific, quantifiable acceptance criteria for its new indication (Treatment of Benign Epidermal Pigmented Lesions) or any other indication. The submission relies on substantial equivalence to predicate devices, implying that the predicates have established safety and effectiveness.
Here's a breakdown of why the requested information cannot be fully provided from the text:
- Table of acceptance criteria and reported device performance: Not available. The document refers to general laser performance standards (21 CFR 1040, EN 60601 1-2) which are safety and electrical standards, not clinical performance criteria. There is no reported clinical performance data.
- Sample size used for the test set and the data provenance: Not applicable, as no clinical test set/study is described.
- Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not applicable, as no clinical test set/study is described.
- Adjudication method for the test set: Not applicable, as no clinical test set/study is described.
- If a multi-reader multi-case (MRMC) comparative effectiveness study was done: No, not mentioned.
- If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: Not applicable, as this is a laser device, not an algorithm.
- The type of ground truth used: Not applicable, as no clinical test set/study is described.
- The sample size for the training set: Not applicable, as no training set for a clinical study is described.
- How the ground truth for the training set was established: Not applicable, as no training set for a clinical study is described.
In summary, this 510(k) relies on the concept of "substantial equivalence" to predicate devices, rather than presenting a new clinical study with specific acceptance criteria and performance data for the device itself.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for Candela. The logo consists of a stylized flame on the left and the word "CANDELA" on the right. The flame is black and white, with the top half being solid black and the bottom half being made up of horizontal white stripes. The word "CANDELA" is in a sans-serif font and is also black.
FEB - 9 2005
510(k) Summary
General Information:
The purpose of this premarket notification application is to provide notification of substantial equivalence of the Candela Family of Family of Pulsed Dye Laser Systems, which are substantially equivalent to previously marketed devices intended for the following indications General Surgery: Photocoagulation of benign cutaneous vascular lesion and benign cutaneous lesions. Dermatology/Plastic Surgery: For treatment of benign cutaneous vascular lesion, such as facial and leg Donnatoregor raine stains, hemangiomas, angioma, spider angioma, Poikiloderma of Civatte, and benign cutaneous lesions, such as warts, scars, striae and psoriasis. and the treatment of wrinkles. Treatment of Inflammatory Acne Vulgaris
Gynecology: Photocoagulation of benign cutaneous lesion and benign vascular lesion in gynecology. Podiatry: Treatment of benign cutaneous lesions, such as warts.
New Indication: Treatment of Benign Epidermal Pigmented Lesions
There have been no modifications in design of the Lasers in the Pulsed Dye Family of Laser Systems which were previously cleared under K001093, K021180, K033331 and K033461.
| Submitted by: | Candela Corporation530 Boston Post RoadWayland, MA 01778-1886 |
|---|---|
| Contact Person: | Lorraine Calzetta |
| Date prepared: | November 12, 2004 |
| Classification: | Class II (21 CFR § 878.4810 Laser Surgical Instrument for usein General and Plastic Surgery and in Dermatology) |
| Common Name: | Dermatology Laser, Family of Pulsed Dye Laser Systems |
Predicate Devices
| CandelaSPTL1BLaser | CandelaCbeamPulsedDyeLaser(aka | CandelaVbeamPulsedDyeLaser | Cynosuree Apogee | Laserscope AuraKTPLaser | GentelLASEFamily oflaserSystems |
|---|---|---|---|---|---|
| -------------------------------- | ---------------------------------------------------- | -------------------------------------------- | ---------------------- | --------------------------------- | ------------------------------------------------- |
{1}------------------------------------------------
Candela Family of Pulsed Dye Laser Systems 510k Summary
| Clearbeam | |||||
|---|---|---|---|---|---|
| am) | |||||
| K001093 | K02118 | K03346 | K031488 | K984424 | K024371 |
| 0 | 1 | K024206 | |||
| K03333 | |||||
| 1 |
Description:
The Candela Family of Pulse Dye Laser Systems are flash-lamp excited pulsed dye medical lasers, controlled by an embedded microprocessor., to be used for the following uses in: General Surgery: Photocoagulation of benign cutaneous vascular lesion and benign cutaneous lesions. For treatment of benign cutaneous vascular lesion, such as facial and leg Dermatology/Plastic Surgery: telangiectasia, rosacea, port wine stains, hemangiomas, angioma, Poikiloderma of Civatte, and benign cutaneous lesions, such as warts, scars, striae and psoriasis. and the treatment of wrinkles. Treatment of Inflammatory Acne Vulgaris
Gynecology: Photocoagulation of benign cutaneous lesion and benign vascular lesion in gynecology. Podiatry: Treatment of benign cutaneous lesions, such as warts.
New Indication: Treatment of Benign Epidermal Pigmented Lesions
The Lasers may be used with the Candela Dynamic Cooling Device, which provides a short burst of cryogen spray prior to firing the laser pulse. The laser output energy is delivered via an optical fiber to a hand piece. The cryogen, which is housed within the laser enclosure, is delivered via a hose to a nozzle located in the hand piece . The Candela Family of Pulsed Dye Laser Systems are equipped with safety interlock systems to protect patients and operators. Users of the device make selections from an onboard control panel to regulate operation during treatment.
Testing:
As a laser product, the Family of Pulsed Dye Laser Systems are required to conform and do conform to the Laser Performance Standard (21 CFR 1040). In addition the lasers conform to the Harmonized Standard EN 60601 1-2, Part 2 established by and required by the European Community.
Summary of Substantial Equivalence:
The Candela Family of Pulsed Dye Laser Systems is equivalent in key design aspects, functional features and indications for use as the predicate devices for the treatment of epidermal pigmented lesions.
On the basis of similarities in functional features, method of operation, and intended uses, Candela Corporation believes that the Candela Family of Pulsed Dye Laser Systems are substantially equivalent to the predicate devices.
{2}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized graphic of three human figures, representing the department's focus on people and their well-being.
Public Health Service
FEB - 9 2005
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Ms. Lorraine Calzetta Patrovic Manager, Regulatory Affairs Candela Corporation 530 Boston Post Road Wayland, Massachusetts 01778
Re: K043251
Trade/Device Name: Candela Family of Pulsed Dye Laser Systems Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: II Product Code: GEX Dated: November 12, 2004 Received: November 23, 2004
Dear Ms. Patrovic:
We have reviewed your Section 510(k) premarket notification of intent to market the device we nave reviewed your been wined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate for ass stated in the encrease of the enactment date of the Medical Device Amendments, or to conimered processified in accordance with the provisions of the Federal Food, Drug, de nees mat have been revat do not require approval of a premarket approval application (PMA). and Cosmetic (11ct) the market the device, subject to the general controls provisions of the Act. The r ou may, arerely missis of the Act include requirements for annual registration, listing of general controll proving practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it If your device is elabilition (sontrols. Existing major regulations affecting your device can may be subject to basil additions, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean 1 loase be advised that i Drivisation of our device complies with other requirements of the Act that I Dri has Intact a and regulations administered by other Federal agencies. You must of any I outer states and regisments, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set CI K ratt 607), adoning (21 CFR Part 820); and if applicable, the electronic forth in the qualis (Sections (Sections 531-542 of the Act); 21 CFR 1000-1050.
{3}------------------------------------------------
Page 2 - Ms. Lorraine Calzetta Patrovic
This letter will allow you to begin marketing your device as described in your Section 510(k) I mis lotter will and w yours ough finding of substantial equivalence of your device to a legally prematics notification. Thesults in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please rr you attire of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small other general mionnational and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Mark A. Wilkerson
Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
Indications for Use
510(k) Number (if known):
Device Name: Candela Family of Pulsed Dye Laser Systems
Indications For Use:
The Candela Family of Pulse Dye Laser Systems is indicated for the following uses in:
General Surgery: Photocoagulation of benign cutaneous vascular lesion and benign cutaneous lesions.
Dermatology/Plastic Surgery: For treatment of benign cutaneous vascular lesion, such as facial and leg telangiectasia, rosacea, port wine stains, hemangiomas, angioma, spider angioma, Poikiloderma of Civatte, and benign cutaneous lesions, such as warts, scars, striae and psoriasis. and the treatment of wrinkles.
Treatment of Inflammatory Acne Vulgaris
Gynecology: Photocoagulation of benign cutaneous lesion and benign vascular lesion in gynecology.
Podiatry: Treatment of benign cutaneous lesions, such as warts.
New Indication: Treatment of Benign Epidermal Pigmented Lesions
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| --------- |
|---|
(k) Number
§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.
(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.